Young C L, Taylor D M
Pharmacy Department, Maudsley Hospital, London, UK.
Acta Psychiatr Scand. 2006 Jul;114(1):14-20. doi: 10.1111/j.1600-0447.2006.00766.x.
Studies have shown oral risperidone and conventional depot antipsychotics decrease direct healthcare costs largely by reducing hospitalization. Our aim was to assess the effect on bed stay of risperidone injection prescribed in normal clinical practice.
Patients prescribed risperidone long-acting injection (RLAI) were identified and followed-up for 1 year. Resource use data were collected for 3 years before and for 1 year after the initiation of RLAI. The main outcome measure was bed stay before and after the prescription of RLAI.
Outcome data were available for 250 subjects. Eighty-one subjects (32.4%) completed 1 year's treatment. Days spent in hospital increased from (mean number/patient) 31 in year -3 to 44 in year -2 to 90 in year -1 to 141 in year +1. Direct healthcare costs increased accordingly. Outcome for RLAI continuers was similar to that of discontinuers.
Switching to RLAI was associated with a continuation of the trend for increased bed stay and use of healthcare resources.
研究表明,口服利培酮和传统长效抗精神病药物主要通过减少住院次数来降低直接医疗成本。我们的目的是评估在正常临床实践中使用利培酮注射剂对住院时间的影响。
确定使用利培酮长效注射剂(RLAI)的患者,并对其进行为期1年的随访。在开始使用RLAI之前的3年和之后的1年收集资源使用数据。主要结局指标是使用RLAI前后的住院时间。
有250名受试者的结局数据可用。81名受试者(32.4%)完成了1年的治疗。住院天数从第-3年的(平均/患者)31天增加到第-2年的44天,第-1年的90天,第+1年的141天。直接医疗成本相应增加。继续使用RLAI的受试者的结局与停药者相似。
改用RLAI与住院时间和医疗资源使用增加的趋势持续存在有关。